Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
Executive Summary
The National Organization for Rare Disorders’ campaign to get FDA to codify a flexible approach on approving orphan drugs is now bolstered by an analysis that concludes most of the agency’s approval decisions for such products already use unconventional efficacy standards.
You may also be interested in...
US FDA Should Offer Formal Declaration Of Orphan Drug Flexibility, Attorney Says
Attorney Frank Sasinowski says the agency should include new "boilerplate language" in official documents describing scientific flexibility for orphan drug approval requirements.
US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA
Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.
US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA
Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.